CHM CDH17 CAR‑T
Gastric, neuroendocrine, and colorectal cancers
Phase 1/2Active
Key Facts
Indication
Gastric, neuroendocrine, and colorectal cancers
Phase
Phase 1/2
Status
Active
Company
About Chimeric Therapeutics
Australian cell‑therapy pioneer advancing CAR‑T and NK‑cell cancer treatments in early clinical trials.
View full company profile